Completed

MK0431 Safety and Efficacy in Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Pioglitazone Therapy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This phase 3 study aims to evaluate the safety and effectiveness of MK0431 in improving glycemic control, specifically by measuring changes in HbA1c levels after 24 weeks, in individuals with Type 2 Diabetes Mellitus who are currently not achieving adequate control with Pioglitazone therapy.

What is being tested

Comparator: Sitagliptin

+ Comparator: Pioglitazone

+ Metformin

Drug
Who is being recruted

Diabetes Mellitus+2

+ Diabetes Mellitus, Type 2

+ Endocrine System Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 3
Interventional
Study Start: June 2004
See protocol details

Summary

Principal SponsorMerck Sharp & Dohme LLC
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 2004

Actual date on which the first participant was enrolled.

The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Official TitleA Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy 
NCT00086502
Principal SponsorMerck Sharp & Dohme LLC
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

353 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Diabetes MellitusDiabetes Mellitus, Type 2Endocrine System DiseasesMetabolic DiseasesGlucose Metabolism Disorders

Criteria

Inclusion Criteria: * Patient has type 2 diabetes mellitus (T2DM) * Patient is 18 years of age (or older) * Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period Exclusion Criteria: * Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis * Patient required insulin within the prior 8 weeks * Patient is on a weight loss program and is not in the maintenance phase * Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks * Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) * Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease * Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) * Patient has any of the following disorders within the past 6 months: Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder. * Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months * Patient has severe peripheral vascular disease * Patient has congestive heart failure * Patient is HIV positive * Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) * Patient has a history of neoplastic disease * Patient has a history of alcohol or drug abuse within the past 3 years * Patient has viral hepatitis (hepatitis B or C)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator
Sitagliptin 100 mg

Group II

Placebo
Placebo

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available. 
CompletedNo study centers